In the present study an ultra-performance convergence chromatography tandem mass spectrometry (UPC2-MS/MS) analytical method was developed and validated for the determination of 17 C19 and 14
C21 steroids, including C11-oxy C19 and C11-oxy
C21 steroids. The limit of detection and limit of quantification ranged from 0.01 to 10 ng/mL and from 0.01 to 20 ng/mL, respectively, and the method shows the recovery, matrix effect and process efficiency of
steroids isolated from a serum matrix to be within acceptable limits. Good accuracy, repeatability and reproducibility were also shown and the method provided excellent sensitivity and selectivity as stereoisomers and regioisomers were also resolved and quantified accurately. Clinical conditions such as
congenital adrenal hyperplasia,
polycystic ovary syndrome in females and
disorders of sex development in neonates and in children, amongst others, are characterized by abnormal
steroid levels.
Steroid profiling is essential to accurately diagnose
steroid levels in the above settings as well as in
androgen excess or deficiency in adrenal-linked
endocrine diseases. Our method, separating C19 and
C21 steroids in a single chromatographic step, offers a reduced sample turnover rate in the clinical setting, while providing comprehensive
steroid profiles of in vivo
steroids in the nmol/L range. This is, to our knowledge, the first method reported to simultaneously separate C19 and
C21 steroids, together with their C11-hydroxy and C11-keto metabolites -one which may hold promise in the identification of new
steroid markers in
steroid-linked
endocrine diseases, in addition to profiling
steroid metabolism and abnormal
enzyme activity in patients.